Omios Biologics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Omios Biologics is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company's core innovation is a patented oncolytic vaccinia virus platform designed with a built-in biomarker for selectivity, aiming to overcome the efficacy-safety trade-offs of earlier OV therapies. With a leadership team possessing deep expertise in virology and biotech, Omios is developing a pipeline of OV therapies, cancer vaccines, and gene delivery vectors, targeting a significant market opportunity in oncology with a focus on combination treatments.

Oncology

Technology Platform

Proprietary oncolytic virus platform based on a novel, modified vaccinia virus (VACV) engineered for cancer selectivity via genetic deletions (e.g., E3L, D10). It features a built-in biomarker, allowing replication only in cancer cells with specific mutations, and is designed for systemic delivery and arming with therapeutic transgenes.

Opportunities

The large, unmet need in solid tumor oncology, especially for metastatic disease, presents a multi-billion dollar market.

The shift toward combination immuno-oncology therapies creates a strong tailwind for a platform designed for safe combination with standard of care.

The versatility of the vaccinia platform also allows expansion into vaccine and gene therapy markets.

Risk Factors

High preclinical/clinical development risk that the novel platform may not demonstrate safety or efficacy in humans.

Intense competition from other immuno-oncology modalities and limited funding windows for early-stage biotechs.

Challenges in manufacturing and scaling up viral vector production for clinical and commercial use.

Competitive Landscape

Omios competes in the oncolytic virus space against approved therapies like T-Vec (Imlygic) and DNX-2401, as well as numerous clinical-stage biotechs (e.g., Replimune, CG Oncology). It also competes broadly within immuno-oncology against checkpoint inhibitors, cell therapies, and antibody-drug conjugates. Its key claimed differentiators are systemic delivery and a biomarker-driven selectivity mechanism.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →